{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:20:28Z","timestamp":1787228428352,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"abstract":"<jats:p>Plant alkaloid-based chemotherapeutic agents, including paclitaxel, vincristine, and irinotecan, play a crucial role in cancer treatment. However, their use is frequently associated with adverse drug events (ADEs), which can impact patient safety and treatment outcomes. Despite prior research, there is still a lack of comprehensive real-world data analysis to systematically investigate ADEs associated with these drugs. This study extracted ADE reports related to paclitaxel, vincristine, and irinotecan from the FDA Adverse Event Reporting System (FAERS) database up to Q4 2024. Data processing was conducted using MySQL and Statistical Analysis System software, and adverse events (AEs) were categorized based on the Medical Dictionary for Regulatory Activities (MedDRA) classification system. Disproportionality analysis was employed using 4 methodologies \u2013 reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and Multi-Item Gamma Poisson Shrinker (MGPS) \u2013 to detect statistically significant safety signals. Additionally, Weibull survival analysis was conducted to evaluate the time-to-onset distribution of ADEs, allowing for a deeper understanding of the temporal patterns of adverse reactions. A total of 31,007, 7389, and 12,049 ADE reports were retrieved for paclitaxel, vincristine, and irinotecan, respectively. Disproportionality analysis identified significant ADE signals across 27 system organ classes, with the most frequently reported AEs involving hematologic, gastrointestinal, neurological, and hepatic disorders. Novel ADE signals were detected for each drug: paclitaxel (10 new signals), vincristine (10 new signals), and irinotecan (8 new signals). Representative newly identified ADEs include dyspnea, flushing, and back pain for paclitaxel, febrile neutropenia, pancytopenia, and sepsis for vincristine, and neuropathy peripheral, malignant neoplasm progression, and pulmonary embolism for irinotecan. Time-to-onset analysis indicated that ADE occurrences predominantly peaked within the first 30 days of treatment, following an early failure pattern, suggesting that intensive monitoring during this period may be necessary. This study provides a comprehensive real-world safety evaluation of plant alkaloid-based chemotherapeutic agents, identifying both known and previously unreported ADEs. By leveraging large-scale FAERS data, multiple signal detection methodologies, and Weibull survival analysis, this research enhances the pharmacovigilance landscape, offering crucial insights for clinicians and regulatory authorities.<\/jats:p>","DOI":"10.1097\/md.0000000000046044","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:01:32Z","timestamp":1764169292000},"page":"e46044","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive pharmacovigilance of phytoalkaloid chemotherapeutics: Signal detection and time-to-onset analysis based on FAERS"],"prefix":"10.1097","volume":"104","author":[{"given":"Bangguo","family":"Song","sequence":"first","affiliation":[{"name":"Clinical College of Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical College of Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China"},{"name":"Key Laboratory of Dunhuang Medicine, Ministry of Education, Gansu University of Chinese Medicine, Lanzhou, China"},{"name":"Research Center of Traditional Chinese Medicine, Gansu Province, Gansu University of Chinese Medicine, Lanzhou, China"},{"name":"Scientific Research and Experimental Center, Gansu University of Chinese Medicine, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Public Health, Gansu University of Chinese Medicine, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6935-8241","authenticated-orcid":false,"given":"Jihong","family":"Hu","sequence":"additional","affiliation":[{"name":"Laboratory and Simulation Training Center, Gansu University of Chinese Medicine, Lanzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260514","doi-asserted-by":"crossref","first-page":"108555","DOI":"10.1016\/j.intimp.2022.108555","article-title":"The interactions of paclitaxel with tumour microenvironment.","volume":"105","author":"Yu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"Pt B","key":"R2-20260514","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biochi.2024.07.017","article-title":"Tailor-made vincristine-liposomes for tumor targeting.","volume":"227","author":"Abawi","year":"2024","journal-title":"Biochimie"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41431-022-01243-2","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.","volume":"31","author":"Hulshof","year":"2023","journal-title":"Eur J Hum Genet"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.3390\/cancers14246203","article-title":"Natural products\/bioactive compounds as a source of anticancer drugs.","volume":"14","author":"Asma","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1177\/10600280211058385","article-title":"Adverse event profile for nanoparticle albumin-bound paclitaxel compared with solvent-based taxanes in solid-organ tumors: a systematic review and meta-analysis of randomized clinical trials.","volume":"56","author":"He","year":"2022","journal-title":"Ann Pharmacother"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/oncolo\/oyab079","article-title":"Vincristine sulfate liposome injection with bendamustine and rituximab as first-line therapy for B-Cell lymphomas: a phase I study.","volume":"27","author":"Ollila","year":"2022","journal-title":"Oncologist"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.3390\/ijms21144919","article-title":"Irinotecan-still an important player in cancer chemotherapy: a comprehensive overview.","volume":"21","author":"Kciuk","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R9-20260514","first-page":"1","article-title":"A real-world pharmacovigilance analysis for demethylation drug: findings from the FDA adverse event reporting database.","volume":"103","author":"Chen","year":"2025","journal-title":"Oncology (Huntingt)"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R11-20260514","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"1425171","DOI":"10.3389\/fphar.2024.1425171","article-title":"Neratinib safety evaluation: real-world adverse event analysis from the FAERS database.","volume":"15","author":"Fan","year":"2024","journal-title":"Front Pharmacol"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/IJN.S480553","article-title":"CD44-receptors-mediated multiprong targeting strategy against breast cancer and tumor-associated macrophages: design, optimization, characterization, and cytologic evaluation.","volume":"20","author":"Hussain","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1038\/s41598-025-92471-1","article-title":"Oral mucosal lesions in polish patients with acute myeloid leukemia after allogeneic hematopoietic cell transplantation.","volume":"15","author":"Wysocka-S\u0142owik","year":"2025","journal-title":"Sci Rep"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.3390\/curroncol31120553","article-title":"Key risk factors, sex differences, and the influence of high-intensity exercise on colorectal carcinogenesis: a 10-year cohort study based on 1,120,377 individuals from the NHISS data.","volume":"31","author":"Jee","year":"2024","journal-title":"Curr Oncol"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.24.00235","article-title":"Single or double induction with 7\u2009+\u20093 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized daunodouble trial by the study alliance leukemia.","volume":"43","author":"R\u00f6llig","year":"2025","journal-title":"J Clin Oncol"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12876-024-03531-1","article-title":"Epidemiology and clinical characteristics of colorectal cancer and advanced adenoma: a single center experience in Jordan.","volume":"25","author":"Khamees","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"R19-20260514","doi-asserted-by":"crossref","first-page":"2439733","DOI":"10.1080\/16078454.2024.2439733","article-title":"Treatment of pediatric acute lymphoblastic leukemia in india as per modified BFM 95 protocol with minimal residual disease monitoring.","volume":"30","author":"Thakkar","year":"2025","journal-title":"Hematology"},{"key":"R20-20260514","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1097\/MJT.0b013e31828232b8","article-title":"Same chemotherapy regimen leads to different myelotoxicity in different malignancies: a comparison of chemotherapy-associated myelotoxicity in patients with advanced ovarian and non-small-cell lung cancer.","volume":"23","author":"Tas","year":"2016","journal-title":"Am J Ther"},{"key":"R21-20260514","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00415-022-11377-4","article-title":"Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity.","volume":"270","author":"Velasco","year":"2023","journal-title":"J Neurol"},{"key":"R22-20260514","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy.","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.tox.2008.04.017","article-title":"Macrophage inflammatory protein-3alpha influences growth of K562 leukemia cells in co-culture with anticancer drug-pretreated HS-5 stromal cells.","volume":"249","author":"Lee","year":"2008","journal-title":"Toxicology"},{"key":"R24-20260514","first-page":"225","article-title":"The course of chemotherapy-induced peripheral neuropathy (CIPN) in hematological patients treated with vincristine, bortezomib, or lenalidomide: the NOVIT study.","volume":"33","author":"Maksten","year":"2025","journal-title":"Support Care Cancer"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"7465","DOI":"10.3390\/molecules27217465","article-title":"Ginger constituent 6-shogaol attenuates vincristine-induced activation of mouse gastroesophageal vagal afferent C-fibers.","volume":"27","author":"Patil","year":"2022","journal-title":"Molecules"},{"key":"R26-20260514","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41416-019-0557-8","article-title":"Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma.","volume":"121","author":"Magni","year":"2019","journal-title":"Br J Cancer"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41416-024-02885-3","article-title":"Phase II study of irinotecan, Trifluridine\/tipiracil (TAS-102) plus bevacizumab as a later-line therapy for patients with metastatic colorectal cancer (mCRC): a prospective single-center explorative study.","volume":"131","author":"Li","year":"2024","journal-title":"Br J Cancer"},{"key":"R28-20260514","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s12253-019-00644-x","article-title":"Irinotecan-induced mucositis is associated with goblet cell dysregulation and neural cell damage in a tumour bearing DA rat model.","volume":"26","author":"Thorpe","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"R29-20260514","doi-asserted-by":"crossref","first-page":"112192","DOI":"10.1016\/j.biopha.2021.112192","article-title":"Selenium-enriched Bifidobacterium longum DD98 attenuates irinotecan-induced intestinal and hepatic toxicity in vitro and in vivo.","volume":"143","author":"Zhu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R30-20260514","doi-asserted-by":"crossref","first-page":"113440","DOI":"10.1016\/j.ejca.2023.113440","article-title":"FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: implications for combination therapies and early response prediction.","volume":"196","author":"van Eijck","year":"2024","journal-title":"Eur J Cancer"},{"key":"R31-20260514","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1111\/cas.14217","article-title":"Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.","volume":"110","author":"Kenmotsu","year":"2019","journal-title":"Cancer Sci"},{"key":"R32-20260514","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.lungcan.2020.05.005","article-title":"Phase I\/II study of carboplatin plus weekly nab-paclitaxel in patients aged \u226575 years with squamous-cell lung cancer: TORG1322.","volume":"146","author":"Zenke","year":"2020","journal-title":"Lung Cancer"},{"key":"R33-20260514","doi-asserted-by":"crossref","first-page":"e35738","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:05:08Z","timestamp":1778756708000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":33,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046044","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2025-07-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}